Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial - Herrlinger, Ulrich; Brehmer, Stefanie; Wick, Wolfgang (The lancet, 2019)
Gesehen am 26.07.2019